Literature DB >> 12270633

Capsaicin receptor immunoreactivity in the human trigeminal ganglion.

Mingyan Hou1, Rolf Uddman, Janos Tajti, Martin Kanje, Lars Edvinsson.   

Abstract

The cloned capsaicin receptor, also known as vanilloid receptor subtype 1 (VR1) receptor, has been demonstrated to be an integral membrane protein with homology to a family of putative store-operated calcium channels. The VR1 receptor is activated not only by capsaicin but also by noxious heat and protons, and therefore it is suggested as a molecular integrator of chemical and physical stimuli that elicit pain. In the present study, indirect immunofluorescence detected a small number of neurons that are VR1 receptor immunoreactive (ir) (171 versus 1038 or 16% of all neuronal cell bodies) in the human trigeminal ganglion (TG). In addition, RT-PCR confirmed the presence of VR1 mRNA in the human TG. It has been hypothesized that TG neuronal cell bodies are the source of capsaicin-stimulated release of calcitonin gene-related peptide (CGRP), and hence co-localization experiments were performed. Around 10% of the VR1 receptor-ir is expressed on neurons that contain CGRP-ir (ten among 74) in the human TG, indicating that capsaicin may act through the VR1 receptor to modulate the release of CGRP and in turn to modulate pain. We observed that 8% of the VR1 receptor-ir neuronal cell bodies contain substance P-ir and 5% nitric oxide synthase. Capsaicin can release nitric oxide, CGRP and substance P from sensory nerves and contribute to central sensitization. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270633     DOI: 10.1016/s0304-3940(02)00741-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  23 in total

Review 1.  Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.

Authors:  Peter J Goadsby
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  New targets for migraine therapy.

Authors:  Amy R Tso; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

3.  Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.

Authors:  E Muñoz-Islas; S Gupta; L R Jiménez-Mena; J Lozano-Cuenca; A Sánchez-López; D Centurión; S Mehrotra; A MaassenVanDenBrink; C M Villalón
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

Review 4.  Emerging drugs for migraine prophylaxis and treatment.

Authors:  Marcelo E Bigal; Abouch V Krymchantowski
Journal:  MedGenMed       Date:  2006-05-04

Review 5.  Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF.

Authors:  Rashid Giniatullin; Andrea Nistri; Elsa Fabbretti
Journal:  Mol Neurobiol       Date:  2008-05-06       Impact factor: 5.590

6.  TRPV1 receptor in the human trigeminal ganglion and spinal nucleus: immunohistochemical localization and comparison with the neuropeptides CGRP and SP.

Authors:  Marina Quartu; Maria Pina Serra; Marianna Boi; Laura Poddighe; Cristina Picci; Roberto Demontis; Marina Del Fiacco
Journal:  J Anat       Date:  2016-07-26       Impact factor: 2.610

7.  The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission.

Authors:  G A Lambert; J B Davis; J M Appleby; B A Chizh; K L Hoskin; A S Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-19       Impact factor: 3.000

8.  Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation.

Authors:  S Akerman; H Kaube; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

9.  Where is TRPV1 expressed in the bladder, do we see the real channel?

Authors:  Wouter Everaerts; M Rosario Sepúlveda; Thomas Gevaert; Tania Roskams; Bernd Nilius; Dirk De Ridder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-20       Impact factor: 3.000

10.  No relevant modulation of TRPV1-mediated trigeminal pain by intranasal carbon dioxide in healthy humans.

Authors:  Tim P Jürgens; Romy Reetz; Arne May
Journal:  J Headache Pain       Date:  2013-04-10       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.